Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

BACKGROUND: Atypical teratoid/thabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a 5-year overall survival rate of 15%–45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Morin, Andrew, Soane, Caroline, Pierce, Angela, Sanford, Bridget, Jones, Kenneth L, Crespo, Michele, Zahedi, Shadi, Vibhakar, Rajeev, Mulcahy Levy, Jean M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236404/
https://www.ncbi.nlm.nih.gov/pubmed/32642704
http://dx.doi.org/10.1093/noajnl/vdaa051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236404/
https://www.ncbi.nlm.nih.gov/pubmed/32642704
http://dx.doi.org/10.1093/noajnl/vdaa051

Ejemplares similares